Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), Thursday said that the U.S. Food and Drug Administration (FDA) has approved a generic version of Novo Nordisk's Saxenda, indicated for adults with obesity.
Teva also announced U.S. launch of the drug.
As of June 2025, Saxenda had annual sales of $165 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.